Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

On November 13, 2024, Amgen filed a BPCIA complaint in the District Court for the Eastern District of North Carolina against Accord Biopharma, Inc.; Accord Healthcare, Inc.; and Intas Pharmaceuticals, ...

On Friday, Amgen Inc (AMGN) stock saw a decline, ending the day at $283.61 which represents a decrease of $-12.32 or -4.16% from the prior close of $295.93. The stock opened at $291.5 and touched a ...

In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson, the plaintiffs successfully overcame a motion to ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...